Expression and Roles of Antimicrobial Peptides in Innate Defense of Airway Mucosa: Potential Implication in Cystic Fibrosis

The treatment of respiratory infections is associated with the dissemination of antibiotic resistance in the community and clinical settings. Development of new antibiotics is notoriously costly and slow; therefore, alternative strategies are needed. Antimicrobial peptides (AMPs), the central effect...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in immunology 2020-06, Vol.11, p.1198
Main Authors: Geitani, Regina, Moubareck, Carole Ayoub, Xu, Zhengzhong, Karam Sarkis, Dolla, Touqui, Lhousseine
Format: Article
Language:English
Subjects:
Animals
antibiotic resistance
antimicrobial effect
antimicrobial peptides
cystic fibrosis
Cystic Fibrosis - immunology
Humans
immune modulation
Immunity, Innate - immunology
Immunology
Life Sciences
Microbiology and Parasitology
Pore Forming Cytotoxic Proteins - immunology
Pore Forming Cytotoxic Proteins - pharmacology
respiratory infections
Respiratory Mucosa - immunology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The treatment of respiratory infections is associated with the dissemination of antibiotic resistance in the community and clinical settings. Development of new antibiotics is notoriously costly and slow; therefore, alternative strategies are needed. Antimicrobial peptides (AMPs), the central effector molecules of the immune system, are being considered as alternatives to conventional antibiotics. Most AMPs are epithelium-derived and play a key role in host defense at mucosal surfaces. They are classified on the basis of their structure and amino acid motifs. These peptides display a range of activities, including not only direct antimicrobial activity, but also immunomodulation and wound repair. In the lung, airway epithelial cells and neutrophils, in particular, contribute to AMP synthesis. The relevance of AMPs for host defense against infection has been demonstrated in animal models and is supported by observations in patient studies, showing altered expression and/or unfavorable circumstances for their action in a variety of lung diseases. Of note, AMPs are active against bacterial strains that are resistant to conventional antibiotics, including multidrug-resistant bacteria. Several strategies have been proposed to use these peptides in the treatment of infections, including direct administration of AMPs. In this review, we focus on studies related to direct bactericidal effects of AMPs and their potential clinical applications with a particular focus on cystic fibrosis.
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2020.01198